Document is current
Any future updates will be listed below
-
Authors
Markowski, Mark C. http://orcid.org/0000-0003-2780-5100
Taplin, Mary-Ellen
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Sena, Laura A.
Wang, Hao http://orcid.org/0000-0001-6489-6940
Qi, Hanfei http://orcid.org/0000-0002-0072-5752
Lalji, Aliya
Sinibaldi, Victoria
Carducci, Michael A.
Paller, Channing J.
Marshall, Catherine H.
Eisenberger, Mario A.
Sanin, David E. http://orcid.org/0000-0003-0188-7267
Yegnasubramanian, Srinivasan http://orcid.org/0000-0003-0744-6606
Gomes-Alexandre, Carolina
Ozbek, Busra
Jones, Tracy
De Marzo, Angelo M. http://orcid.org/0000-0003-4847-5307
Denmeade, Samuel R.
Antonarakis, Emmanuel S.
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
U.S. Department of Defense
- License Information
-
More Information
Article History
Received: 5 July 2023
Accepted: 15 December 2023
First Online: 2 January 2024
Competing interests
: M.C.M. is a paid consultant to Clovis Oncology and Exelixis. E.S.A. has served as a paid consultant for Janssen, Astellas, Sanofi, Bayer, Bristol Myers Squibb, Amgen, Constellation, Blue Earth, Exact Sciences, Invitae, Curium, Pfizer, Merck, AstraZeneca, Clovis, and Eli Lilly; has received research support (to his institution) from Janssen, Johnson & Johnson, Sanofi, Bristol Myers Squibb, Pfizer, AstraZeneca, Novartis, Curium, Constellation, Celgene, Merck, Bayer, Clovis and Orion; and is a co-inventor of a biomarker technology that has been licensed to Qiagen. R.R.A. has served as a paid consultant for Janssen, Bayer, Pfizer, Amgen, Merck, AstraZeneca, Lumanity, Deallus, OncLive, EcoR1, Novartis; has received research support (to his institution) from Janssen, Merck, AstraZeneca, Zenith Epigenetics, Amgen, Novartis. The remaining authors declare no other competing interests.
